Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.

[1]  M. Boerries,et al.  Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms , 2018, Science Translational Medicine.

[2]  Jen-Chin Wang,et al.  Derangements of Toll-like Receptors, Inflammatory Cytokines, and Reactive Oxygen Species in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm: Implicate Roles of Inflammation in the Pathogenesis , 2016 .

[3]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[4]  Jen-Chin Wang,et al.  Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. , 2016, Leukemia research.

[5]  S. Mocellin,et al.  Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression , 2015, Oncotarget.

[6]  R. Ahmed,et al.  Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection , 2014, The Journal of experimental medicine.

[7]  C. Blank,et al.  Interferon‐induced programmed death‐ligand 1 (PD‐L1/B7‐H1) expression increases on human acute myeloid leukemia blast cells during treatment , 2014, European journal of haematology.

[8]  M. Postow,et al.  Checkpoint blocking antibodies in cancer immunotherapy , 2014, FEBS letters.

[9]  Jen-Chin Wang,et al.  Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression and Myeloid Derived Suppressor Cells (MDSC) In Myeloid Neoplasms Implicate The Mechanism Of IMiD Treatment Of Myelofibrosis , 2013 .

[10]  E. Cesarman,et al.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. , 2013, Blood.

[11]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[12]  Michael R. Green,et al.  Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy , 2012, Clinical Cancer Research.

[13]  A. Intlekofer,et al.  T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection , 2011, Nature Immunology.

[14]  Michael R. Green,et al.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.

[15]  B. Quesnel,et al.  In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors , 2010, Cancer Immunology, Immunotherapy.

[16]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[17]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[18]  R. Ahmed,et al.  NFATc1 Regulates PD-1 Expression upon T Cell Activation1 , 2008, The Journal of Immunology.

[19]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[20]  Yuqiang Ji,et al.  Clinical significance of B7-H1（PD-L1）expression in human acute leukemia , 2008, Cancer biology & therapy.

[21]  R. Yamamoto,et al.  PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. , 2007, Blood.

[22]  T. Okazaki,et al.  PD-1 and PD-1 ligands: from discovery to clinical application. , 2007, International immunology.

[23]  B. Quesnel,et al.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.

[24]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[25]  J. Cheville,et al.  PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[26]  Lieping Chen,et al.  Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐γ‐induced upregulation of B7‐H1 (CD274) , 2006, FEBS letters.

[27]  Lieping Chen,et al.  Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia , 2005, Clinical Cancer Research.

[28]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[30]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[31]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.